254 related articles for article (PubMed ID: 34758887)
1. Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.
Hoffman KA; Baker R; Fanucchi LC; Lum PJ; Kunkel LE; Ponce Terashima J; McCarty D; Jacobs P; Korthuis PT
Addict Sci Clin Pract; 2021 Nov; 16(1):67. PubMed ID: 34758887
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
Korthuis PT; Lum PJ; Vergara-Rodriguez P; Ahamad K; Wood E; Kunkel LE; Oden NL; Lindblad R; Sorensen JL; Arenas V; Ha D; Mandler RN; McCarty D;
Addiction; 2017 Jun; 112(6):1036-1044. PubMed ID: 28061017
[TBL] [Abstract][Full Text] [Related]
3. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.
Korthuis PT; Cook RR; Lum PJ; Waddell EN; Tookes H; Vergara-Rodriguez P; Kunkel LE; Lucas GM; Rodriguez AE; Bielavitz S; Fanucchi LC; Hoffman KA; Bachrach K; Payne EH; Collins JA; Matthews A; Oden N; Jacobs P; Jelstrom E; Sorensen JL; McCarty D
Addiction; 2022 Jul; 117(7):1961-1971. PubMed ID: 35129242
[TBL] [Abstract][Full Text] [Related]
4. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
5. Patients' perspectives on initiating treatment with extended-release naltrexone (XR-NTX).
Gauthier P; Greco P; Meyers-Ohki S; Desai A; Rotrosen J
J Subst Abuse Treat; 2021 Mar; 122():108183. PubMed ID: 33162260
[TBL] [Abstract][Full Text] [Related]
6. Extended-release naltrexone for youth with opioid use disorder.
Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
[TBL] [Abstract][Full Text] [Related]
7. Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
Levin FR; Mariani JJ; Pavlicova M; Choi CJ; Basaraba C; Mahony AL; Brooks DJ; Naqvi N; Bisaga A
Drug Alcohol Depend; 2021 Feb; 219():108482. PubMed ID: 33418204
[TBL] [Abstract][Full Text] [Related]
8. Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.
Marciuch A; Brenna IH; Weimand B; Solli KK; Tanum L; Røstad BK; Birkeland B
Addict Sci Clin Pract; 2022 Jul; 17(1):36. PubMed ID: 35850782
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
Farabee D; Condon T; Hallgren KA; McCrady B
J Subst Abuse Treat; 2020 Oct; 117():108076. PubMed ID: 32811623
[TBL] [Abstract][Full Text] [Related]
10. 'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study.
Brenna IH; Marciuch A; Birkeland B; Veseth M; Røstad B; Løberg EM; Solli KK; Tanum L; Weimand B
J Subst Abuse Treat; 2022 May; 136():108667. PubMed ID: 34865937
[TBL] [Abstract][Full Text] [Related]
11. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
Shulman M; Choo TH; Scodes J; Pavlicova M; Wai J; Haenlein P; Tofighi B; Campbell ANC; Lee JD; Rotrosen J; Nunes EV
J Subst Abuse Treat; 2021 May; 124():108292. PubMed ID: 33771287
[TBL] [Abstract][Full Text] [Related]
12. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
[TBL] [Abstract][Full Text] [Related]
14. Attitudes toward extended-release naltrexone treatment for opioid use disorder among African Americans.
Rigg KK
Drug Alcohol Depend; 2024 Apr; 257():111260. PubMed ID: 38492256
[TBL] [Abstract][Full Text] [Related]
15. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
Lier AJ; Seval N; Vander Wyk B; Di Paola A; Springer SA
J Subst Abuse Treat; 2022 Nov; 142():108852. PubMed ID: 35988513
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
[TBL] [Abstract][Full Text] [Related]
18. Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study.
Greiner MG; Shulman M; Opara O; Potter K; Voronca DC; Tafessu HM; Hefner K; Hamilton A; Scheele C; Ho R; Dresser L; Jelstrom E; Fishman M; Ghitza UE; Rotrosen J; Nunes EV; Bisaga A
Contemp Clin Trials; 2023 May; 128():107148. PubMed ID: 36931426
[TBL] [Abstract][Full Text] [Related]
19. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
Springer SA; Di Paola A; Azar MM; Barbour R; Biondi BE; Desabrais M; Lincoln T; Skiest DJ; Altice FL
J Acquir Immune Defic Syndr; 2018 May; 78(1):43-53. PubMed ID: 29373393
[TBL] [Abstract][Full Text] [Related]
20. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.
Jarvis BP; Holtyn AF; Berry MS; Subramaniam S; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
J Subst Abuse Treat; 2018 Feb; 85():38-44. PubMed ID: 28449955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
